CJC-1295 and Ipamorelin: The Growth Hormone Peptide Stack Explained
Last reviewed and updated: May 5, 2026 — medically reviewed by Dr. Jonathann Kuo, MD.
Peptide stacks are the new Growth hormone production drops roughly 15% every decade after age 30. That decline shows up as stubborn body fat, poor sleep, slow recovery, and thinning skin. CJC 1295 and ipamorelin have emerged as the most widely prescribed peptide combination in regenerative medicine because they restore growth hormone output without injecting synthetic HGH.
Interested in peptide therapy? Find vetted peptide therapy clinics near you.
This stack uses two different signaling pathways to amplify the body’s own pulsatile growth hormone release.
Clinicians across the United States now prescribe this combination for body composition, sleep quality, injury recovery, and overall vitality. Here is everything patients and practitioners need to know about how this peptide stack works, what results to expect, and what the current evidence shows. The growing interest in peptide therapy has made this stack one of the most requested treatments in regenerative medicine.
| What This Stack Does For You | What You Actually Notice |
|---|---|
| Restores growth hormone the natural way | Unlike HGH injections, this stack tells your pituitary gland to produce its own growth hormone — preserving your body’s natural rhythms and feedback systems instead of bypassing them. |
| Deeper sleep within 1 to 2 weeks | Sleep is usually the first thing patients notice. Growth hormone peaks naturally during deep sleep, and this stack amplifies that surge. Most people report more restorative, restful nights within the first two weeks. |
| Reduces body fat over 4 to 6 months | Elevated growth hormone drives the breakdown of stored fat. Most patients lose 10 to 20 pounds of body fat over a full treatment cycle — particularly around the abdomen. |
| Builds lean muscle | Growth hormone and IGF-1 support protein synthesis. Lean muscle gains of 3 to 8 pounds are typical over the same 4 to 6 month cycle, especially with consistent resistance training. |
| Thicker hair, better skin, stronger nails | Collagen production increases with elevated growth hormone. Patients notice improved skin elasticity, reduced fine lines, thicker hair, and stronger nails over 3 to 6 months of therapy. |
| Faster recovery and less soreness | Higher IGF-1 speeds repair of muscle, tendons, and connective tissue. Joint discomfort and post-workout soreness typically diminish within 4 to 8 weeks. |
| Available through licensed clinics at $200 to $500 per month | Neither peptide is FDA approved, but licensed physicians prescribe them through compounding pharmacies. Cost is significantly lower than direct HGH therapy, which can run $1,000 to $3,000 per month. |
What Is CJC 1295?
CJC 1295 is a synthetic analog of growth hormone releasing hormone (GHRH). The natural GHRH peptide produced by the hypothalamus breaks down within minutes. CJC 1295 includes amino acid modifications that extend its half life dramatically. The version without DAC (Drug Affinity Complex) has a half life of roughly 30 minutes, producing controlled bursts that closely mimic natural physiology. The version with DAC binds to albumin in the bloodstream and remains active for 6 to 8 days.
Most clinics prescribe the no DAC version (also called modified GRF 1 29) for peptide stacking. This form produces a sharp, clean growth hormone pulse and clears the body quickly. That fast clearance allows patients to stack it with ipamorelin for a coordinated release pattern without sustained elevation that can cause side effects.
What Is Ipamorelin?
Ipamorelin belongs to the growth hormone releasing peptide (GHRP) class. It mimics the hunger hormone ghrelin and binds to the growth hormone secretagogue receptor (GHS R1a) on pituitary cells. This triggers an immediate, strong pulse of growth hormone release. Ipamorelin has a short half life of about 2 hours.
What sets ipamorelin apart from other GHRPs like GHRP 6 or GHRP 2 is its selectivity. Ipamorelin stimulates growth hormone release without significantly increasing cortisol, prolactin, or aldosterone. That selectivity translates to fewer side effects. Patients do not experience the intense hunger spikes associated with GHRP 6 or the cortisol elevation seen with hexarelin.
Why These Two Peptides Work Better Together
The CJC 1295 and ipamorelin stack works because each peptide activates a completely different receptor system on pituitary somatotroph cells. CJC 1295 binds to the GHRH receptor and activates the cAMP/PKA signaling cascade. Ipamorelin binds to the GHS R1a receptor and activates the phospholipase C pathway, increasing intracellular calcium.
Research shows that co activation of both receptor systems produces a cAMP response approximately twice that of GHRH receptor activation alone. In practical terms, the stack produces growth hormone pulses 3 to 5 times larger than either compound administered individually. CJC 1295 increases the number of pituitary cells that respond to the ghrelin signal, while ipamorelin amplifies the magnitude of each cell’s growth hormone release. The combination creates a powerful, synergistic effect that no single peptide can replicate.
GHRH Pathway vs. Ghrelin Mimetic Pathway
Understanding the two receptor systems clarifies why this stack delivers superior results.
The GHRH Pathway (CJC 1295): The hypothalamus releases GHRH in natural pulses. CJC 1295 mimics this signal by binding to the GHRH receptor on somatotroph cells. This activates adenylyl cyclase, increases cAMP production, and stimulates both the synthesis and secretion of growth hormone. Think of this as turning up the baseline production capacity.
The Ghrelin Pathway (Ipamorelin): Ghrelin originates primarily from the stomach and acts on the GHS R1a receptor. Ipamorelin mimics this signal. The ghrelin receptor stimulates the secretion (but not synthesis) of stored growth hormone. Think of this as triggering the release of growth hormone the pituitary has already manufactured. The GHS R1a receptor also exhibits constitutive activity, meaning it maintains a tonic signal that supports normal growth hormone output even without a ligand present.
Together, CJC 1295 increases production while ipamorelin triggers release. Both signals converge on the same somatotroph cells, creating an amplified pulse that follows the body’s natural rhythm.
Clinical Benefits of the Stack
Body Composition
Growth hormone drives lipolysis (fat breakdown) and protein synthesis. Patients using the CJC 1295 and ipamorelin stack report losing 10 to 20 pounds of body fat over 4 to 6 months. Lean muscle gains of 3 to 8 pounds occur in the same timeframe. IGF 1 levels typically rise 20 to 30% above baseline, supporting tissue growth and repair throughout the body. These changes require consistent dosing combined with resistance training and adequate protein intake.
Sleep Quality
Growth hormone secretion peaks during deep sleep. Administering the stack before bed amplifies this natural surge. Patients consistently report improved sleep quality within the first 1 to 2 weeks of treatment. Deeper sleep further supports recovery, cognitive function, and metabolic health. Sleep improvement is typically the earliest noticeable benefit.
Recovery and Repair
Elevated growth hormone and IGF 1 accelerate the repair of muscle, tendon, and connective tissue. Athletes and active adults experience faster recovery between training sessions. Joint discomfort and general soreness diminish over the first 4 to 8 weeks. Surgical recovery and injury rehabilitation also benefit from enhanced tissue repair.
Anti Aging and Skin Health
Growth hormone stimulates collagen production. Patients report improved skin elasticity, reduced fine lines, and thicker hair over 3 to 6 months of therapy. Increased cellular turnover contributes to a more youthful appearance. Nail strength and wound healing speed also improve.
How Dosing Works
The standard clinical protocol calls for subcutaneous injections of 200 mcg CJC 1295 (no DAC) combined with 200 mcg ipamorelin. Most clinics prescribe injections 5 days per week with 2 days off. Evening administration before bed aligns the growth hormone pulse with the body’s natural nocturnal secretion pattern.
Body weight affects dosing. Patients under 150 pounds typically use 100 to 150 mcg of each peptide. Those between 150 and 200 pounds follow the standard 200 mcg protocol. Patients between 200 and 250 pounds use 250 to 300 mcg. Those above 250 pounds use up to 300 mcg of each peptide. The 5 on, 2 off schedule prevents receptor desensitization and maintains effectiveness over long treatment cycles. Research on growth hormone secretagogues published in Endocrine Reviews details the receptor mechanisms behind this dosing approach.
Most protocols run for 3 to 6 months followed by a 1 to 2 month break. Blood work before, during, and after treatment tracks IGF 1 levels, fasting glucose, and overall metabolic markers.
Side Effects and Safety Profile
The CJC 1295 and ipamorelin stack carries a mild side effect profile compared to other growth hormone therapies. The most commonly reported effects include:
- Mild water retention during the first 2 to 4 weeks
- Occasional headaches, particularly at treatment initiation
- Redness or irritation at the injection site
- Tingling or numbness in the extremities
- Short term fatigue or flushing after injection
Ipamorelin’s selectivity provides a meaningful safety advantage. It does not elevate cortisol, prolactin, or aldosterone at therapeutic doses. This distinguishes it from GHRP 6 and hexarelin, which stimulate appetite and raise cortisol. Serious adverse events remain rare in clinical reporting. Patients with active cancer, uncontrolled diabetes, or pituitary disorders should not use growth hormone secretagogues without direct specialist oversight.
Who Is a Good Candidate?
The CJC 1295 and ipamorelin stack suits adults experiencing age related decline in growth hormone production. Ideal candidates include:
- Adults over 30 seeking to improve body composition despite consistent exercise and nutrition
- Athletes and active adults looking to accelerate recovery and reduce injury downtime
- Patients experiencing poor sleep quality unresponsive to standard interventions
- Adults interested in anti aging benefits including skin, hair, and energy improvements
- Individuals who want growth hormone support without the cost and risks of direct HGH therapy
Candidates should have baseline blood work showing declining IGF 1 levels and no contraindications to growth hormone stimulation. Women who are pregnant or nursing should avoid peptide therapy. Patients with a history of cancer require clearance from their oncologist.
How Clinics Prescribe the Stack
Licensed clinics follow a structured protocol. The process begins with a comprehensive consultation that includes medical history review and symptom assessment. Blood work establishes baseline IGF 1, metabolic panel, and hormonal markers. The prescribing physician determines appropriate dosing based on body weight, lab values, and treatment goals.
Compounding pharmacies prepare the peptide combination as a lyophilized powder requiring reconstitution with bacteriostatic water. Patients receive training on proper injection technique, storage requirements (refrigeration), and injection site rotation. Follow up labs at 4 to 6 weeks and 12 weeks monitor IGF 1 response and safety markers. Dose adjustments occur based on lab results and clinical response.
Telemedicine platforms have expanded access to peptide therapy. Many clinics now offer remote consultations, home delivery of peptides, and virtual follow up appointments. Patients should verify that any prescribing clinic uses a licensed 503A or 503B compounding pharmacy.
CJC 1295/Ipamorelin vs. Direct HGH Therapy
CJC 1295/Ipamorelin vs Direct HGH: Side by Side
This comparison highlights the key differences between stimulating your own growth hormone production versus injecting synthetic HGH directly.
Synthetic human growth hormone (somatropin) has served as the standard of care for growth hormone deficiency for decades. Direct HGH therapy introduces exogenous growth hormone into the body at a fixed dose. The CJC 1295 and ipamorelin stack takes a fundamentally different approach by stimulating the pituitary to produce and release its own growth hormone. That distinction carries significant clinical implications.
Direct HGH delivers a flat, supraphysiologic dose that bypasses the body’s feedback loops. Over time, this can suppress the pituitary’s own production and create dependence. Side effects of HGH therapy include carpal tunnel syndrome, joint pain, insulin resistance, edema, and gynecomastia. HGH also carries a substantially higher cost, typically ranging from $1,000 to $3,000 per month.
The CJC 1295 and ipamorelin stack preserves the body’s natural pulsatile rhythm. The pituitary still regulates output through feedback mechanisms. This reduces the risk of excessive growth hormone levels and keeps side effects mild. The cost typically ranges from $200 to $500 per month depending on the clinic and dosing protocol. The tradeoff is that the stack produces more modest growth hormone elevation compared to pharmaceutical HGH doses. Patients with severe growth hormone deficiency diagnosed through stimulation testing still require prescription HGH under endocrinologist supervision.
Current Regulatory Status
Neither CJC 1295 nor ipamorelin holds FDA approval for any human indication. These peptides have existed in a regulatory gray area. In September 2024, the FDA removed both substances from Category 2 of the interim 503A bulks list. This did not clear them for compounding. Instead, the FDA referred them to the Pharmacy Compounding Advisory Committee (PCAC) for further review.
At the December 2024 PCAC meeting, the committee evaluated CJC 1295 in multiple forms including the DAC variant. The committee recommended against inclusion in the 503A Bulks Regulation, effectively suspending compounding availability while evaluation continues. This regulatory uncertainty affects patient access and varies by state.
Patients seeking this therapy should work only with clinics that source from licensed compounding pharmacies operating under current federal and state regulations. The regulatory landscape for peptide therapy continues to evolve, and patients should discuss current availability with their prescribing clinician.
Practical Takeaways
The CJC 1295 and ipamorelin stack remains one of the most evidence backed peptide combinations for restoring healthy growth hormone levels. It amplifies the body’s own production through two complementary receptor pathways. The side effect profile stays mild because ipamorelin targets growth hormone release without disturbing cortisol, prolactin, or appetite regulation.
Expect sleep improvements within 2 weeks and visible body composition changes by week 8 to 12. Follow the 5 on, 2 off dosing schedule. Get baseline and follow up blood work. Work with a licensed clinic that uses a reputable compounding pharmacy. Combine peptide therapy with consistent resistance training, adequate protein intake, and quality sleep habits for the best results.
This stack does not replace prescription HGH for patients with diagnosed severe growth hormone deficiency. It serves adults experiencing the gradual decline in growth hormone that accompanies aging and want to restore their levels using the body’s own production capacity. Discuss candidacy, dosing, and monitoring with a qualified clinician before starting treatment.
Frequently Asked Questions
What is CJC-1295 Ipamorelin used for?
The CJC-1295 and Ipamorelin peptide stack is used for natural growth hormone optimization. Common goals include improved body composition, better sleep quality, faster muscle recovery, anti aging effects, and increased energy. It is prescribed off label by peptide clinics for healthy adults seeking wellness benefits.
Is CJC-1295 Ipamorelin safe?
The stack has a favorable safety profile when prescribed by a licensed provider and sourced from a reputable compounding pharmacy. Short term side effects may include injection site redness, mild flushing, and transient tingling. Long term safety data is limited since these compounds are not FDA approved.
How much does CJC-1295 Ipamorelin cost?
Monthly costs typically range from $150 to $400 at reputable peptide clinics. Pricing depends on dose, compounding pharmacy source, and whether the clinic bundles lab work and follow up visits. Most peptide therapy is cash pay and not covered by insurance.
How long does it take for CJC-1295 Ipamorelin to work?
Most patients notice improved sleep quality within 2 weeks of starting daily injections. Energy and recovery benefits appear around week 3 to 4. Body composition changes typically emerge after 2 to 3 months of consistent use alongside proper nutrition and training.
